Safety and Performance of MIRASOL® PRT Treated Platelet Transfusion Products

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

EARLY_PHASE1

Total Enrollment

118 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-12-31

Study Completion Date

2007-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of the study is to measure platelet corrected count increments and the incidence of serious adverse events (SAE). The primary endpoint is the platelet corrected count increment measured 1-hour post transfusion in response to the infusion of platelet concentrates treated with the Mirasol PRT System device (test product) versus untreated (reference product).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Survival and Recovery of Radio-labeled Platelets Derived From Mirasol-treated Whole Blood

NCT02330081

Blood Safety

COMPLETED NA

Mirasol-Treated Platelets - (Pathogen Reduction Extended Storage Study)

NCT01368211

Thrombocytopenia

TERMINATED PHASE2/PHASE3

Efficacy of Mirasol-treated Apheresis Platelets in Patients With Hypoproliferative Thrombocytopenia

NCT02964325

Hematologic Malignancies Hypoproliferative Thrombocytopenia

TERMINATED NA

Platelet Products Tested With the ThromboLUX® Platelet Quality Test

NCT02158416

Poor Platelet Transfusion Outcome

COMPLETED

Therapeutic Plasma Exchange as an Adjunctive Strategy to Treat Coagulopathy and Inflammation in Severe Covid-19

NCT04613986

Severe Covid-19

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The objective of the study is to determine if the MIRASOL Pathogen Reduction Technology (PRT) System for Platelets device performs safely and maintains adequate platelet performance in a clinical setting. This will be achieved by comparing the platelet corrected count increment measured 1 hour post transfusion and the incidence of serious adverse events in response to the infusion of platelet concentrates treated with the device (test product) versus untreated (reference product) in thrombocytopenic subjects requiring platelet transfusions. The performance, safety, and tolerability profile of the device will be further assessed by monitoring and comparing the incidence of discontinuations due to adverse events in relation to platelet transfusion up to 4 weeks after transfusion, including the incidence of transfusion associated infections, and the number and time between transfusions.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Thrombocytopenia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Treatment, Mirasol-treated platelets

Group Type EXPERIMENTAL

Pathogen Reduction Technology

Intervention Type DEVICE

2

Reference, Untreated platelets

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pathogen Reduction Technology

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female of age of 16 years or older
* Women of Child Bearing Potential not pregnant
* Subject must have signed and dated the Informed Consent form
* Hospitalized, thrombocytopenic subjects and expected to receive at least two platelets transfusion

Exclusion Criteria

* History of any hypersensitivity reaction to riboflavin or metabolites
* History of refractoriness to platelet transfusions
* Positive lymphocytotoxic antibody test
* Active bleeding
* Splenomegaly
* Acute or chronic Disseminated Intravascular Coagulation
* History or diagnosis of Immune/Idiopathic Thrombocytopenic Purpura, Thrombotic Thrombocytopenia Purpura, or Haemolytic Uremic Syndrome
* History or diagnosis of an autoimmune disease affecting haemostasis
* History of solid organ transplants
* Evidence of occlusive venous disease
* Clinical signs of infection at the time of inclusion
* Pregnant or lactating females
* Chronic alcohol misuse
* Use of prohibited medications

Minimum Eligible Age

16 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No